Stocktoria
NovaBridge Biosciences NBP
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-01-17
NovaBridge Biosciences financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $632,000 | -$1.6M | $88.0M |
| R&D expense | $62.9M | $21.8M | $21.4M | $22.5M | $190.3M |
| Operating income | -$94.3M | -$51.4M | -$72.0M | -$53.1M | — |
| Interest expense | — | — | $102,000 | $1,000 | $0 |
| Income tax | $0 | $0 | $0 | $103,000 | -$495,000 |
| Net income | -$46.3M | -$22.2M | -$207.7M | -$371.1M | -$365.9M |
| EPS (diluted) | $-0.21 | $-0.12 | $-1.09 | $-1.96 | $-2.09 |
| Operating cash flow | -$20.6M | -$52.7M | -$183.8M | -$159.9M | -$152.7M |
| Free cash flow | -$20.6M | -$52.7M | -$184.0M | -$162.0M | -$157.4M |
| Cash & equivalents | $210.6M | $68.3M | $291.5M | $342.9M | $552.9M |
| Inventory | — | — | — | $0 | $4.3M |
| Total assets | $260.5M | $212.7M | $368.9M | $590.6M | $878.9M |
| Total liabilities | $29.6M | $11.5M | $126.3M | $168.7M | $163.5M |
| Shareholders' equity | $230.9M | $201.2M | $242.6M | $417.8M | $715.1M |
Source: SEC EDGAR filings · CIK 0001778016 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.